Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05483049
Other study ID # liver injury-grey zone
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date August 31, 2023

Study information

Verified date August 2022
Source Ruijin Hospital
Contact Mingyang Feng
Phone +8619821371901
Email fengmingyang1@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To explore whether normal alanine aminotransferase (ALT) is associated with liver injury in a cohort of hepatitis B virus (HBV) infected patients in grey zone


Description:

Hepatitis B is caused by HBV infection, which can progress to chronic HBV infection after 6 months. HBV infection is a global public health problem, which can affect liver function and even threaten life health. HBV infection is worldwide prevalent, but the infection rate varies greatly in different regions. According to World Health Organization (WHO), there are about 257 million chronic HBV infections worldwide. The western Pacific region and Africa are the most prevalent regions of HBV, with the adult infection rate of 6.2% and 6.1% respectively. Most of Asia is a medium-high epidemic area 1. In 2014, Center for Disease Control and Prevention (CDC) conducted a serological epidemiological survey on hepatitis B among the population aged 1-29 in China, and the results showed that the prevalence rate of HBsAg in the population aged 1-4, 5-14 and 15-29 was 0.32%, 0.94% and 4.38%, respectively. It is estimated that the prevalence of HBsAg in the general population of China is 5-6%, and there are about 70 million chronic HBV infections, among which there are about 20-30 million chronic hepatitis B (CHB) patients. Chronic HBV infection increases the risk of liver fibrosis and hepatocellular carcinoma (HCC). The annual incidence of cirrhosis is 2-10% in CHB patients without antiviral therapy, and the annual incidence of HCC in patients with cirrhosis is 3-6%2. The China 2019 Prevention and Treatment Guidelines of Chronic Hepatitis B recommend that patients with positive HBV DNA and elevated ALT, and those above 30 years old with family history of liver cirrhosis or HCC should initiate antiviral treatment, after ruling out other potential causes. However, the guideline did not identify the specific reference value of upper limit of normal for ALT, neither with cut off value of HBV detection. In addition, there is no clear definition of 'family history'. So, the fuzzy boundaries in the HBV guidelines may cause confusion when providing treatment recommendations in clinical practice and the value of this study would contribute to solve this kind of problems. In a recently published study this year, 432 CHB patients who had liver biopsy in Ruijin Hospital during 2011-2017 were reviewed. So based on this, In the present study, we estimated a sample size of 600.Chronic HBV infected patients from 4 sites who underwent liver biopsy between 2008 and 2020.12 will be enrolled. Previous studies have shown that a high proportion of HBV-infected patients with normal ALT have significant liver injury, including significant inflammation or fibrosis, and even cirrhosis. And studies also show that treatment naive patients with normal ALT, either HBeAg-positive or HBeAg-negative, have a higher risk of developing HCC and even death than those in immune-active patients who received antiviral treatment (AVT). Therefore, early identification of patients with normal ALT but with significant liver inflammation or fibrosis is crucial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 600
Est. completion date August 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Treatment naïve - serum HBsAg positive for >6 months - Grey zone 1: HBeAg (+), HBV DNA >20 but < 107IU/mL, ALT =40 U/L - Grey zone 2: HBeAg (-), HBV DNA > 2000 IU/mL, ALT =40 U/L Exclusion Criteria: - Co-infection with HCV, HDV or HIV - decompensated cirrhosis - other chronic liver diseases

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ruijin Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of significant liver fibrosis. Prevalence of significant liver fibrosis (G=2) in patients in all patients. from Jan, 2008 to December, 2021
Primary Prevalence of significant liver inflammation. Prevalence of significant liver inflammation (S=2) in patients in all patients. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis in different age group in grey zone 1. Prevalence of significant liver fibrosis (G=2) in different age group (10 years old per group) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation in different age group in grey zone 1. Prevalence of significant liver inflammation (S=2) in different age group (10 years old per group) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis in different age group in grey zone 2. Prevalence of significant liver fibrosis (G=2) in different age group (10 years old per group) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation in different age group in grey zone 2. Prevalence of significant liver inflammation (S=2) in different age group (10 years old per group) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis at different ALT level in grey zone 1. Prevalence of significant liver fibrosis (G=2)at different ALT level (low normal level 0-25 U/L for women and 0-35 U/L for men, high normal level 26-40 U/L for women and 36-40 U/L for men) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation at different ALT level in grey zone 1. Prevalence of significant liver inflammation (S=2) at different ALT level (low normal level 0-25 U/L for women and 0-35 U/L for men, high normal level 26-40 U/L for women and 36-40 U/L for men) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis at different ALT level in grey zone 2. Prevalence of significant liver fibrosis (G=2)at different ALT level (low normal level 0-25 U/L for women and 0-35 U/L for men, high normal level 26-40 U/L for women and 36-40 U/L for men) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation at different ALT level in grey zone 2. Prevalence of significant liver inflammation (S=2) at different ALT level (low normal level 0-25 U/L for women and 0-35 U/L for men, high normal level 26-40 U/L for women and 36-40 U/L for men) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis at different DNA level in grey zone 1. Prevalence of significant liver fibrosis (G=2) at different DNA level (log10 IU/mL per group) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation at different DNA level in grey zone 1. Prevalence of significant liver inflammation (S=2) at different DNA level (log10 IU/mL per group) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis at different DNA level in grey zone 2. Prevalence of significant liver fibrosis (G=2) at different DNA level (log10 IU/mL per group) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation at different DNA level in grey zone 2. Prevalence of significant liver inflammation (S=2) at different DNA level (log10 IU/mL per group) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis with different family history of HCC in grey zone 1. Prevalence of significant liver fibrosis (G=2) with different family history of HCC or liver cirrhosis (first degree relative, second and third degree relatives) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation with different family history of HCC in grey zone 1. Prevalence of significant liver inflammation (S=2) with different family history of HCC or liver cirrhosis (first degree relative, second and third degree relatives) in patients in grey zones 1. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver fibrosis with different family history of HCC in grey zone 2. Prevalence of significant liver fibrosis (G=2) with different family history of HCC or liver cirrhosis (first degree relative, second and third degree relatives) in patients in grey zones 2. from Jan, 2008 to December, 2021
Secondary Prevalence of significant liver inflammation with different family history of liver cirrhosis in grey zone 2. Prevalence of significant liver inflammation (S=2) with different family history of HCC or liver cirrhosis (first degree relative, second and third degree relatives) in patients in grey zones 2. from Jan, 2008 to December, 2021
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A